Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non–muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin-Reference-Cited by-同舟云学术

Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non–muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin

Published:2020-09 Issue:3 Volume:78 Page:387-399
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Li Roger^ORCID,Sundi Debasish^ORCID,Zhang Jingsong,Kim Youngchul,Sylvester Richard J.,Spiess Philippe E.,Poch Michael A.,Sexton Wade J.,Black Peter C.,McKiernan James M.,Steinberg Gary D.,Kamat Ashish M.,Gilbert Scott M.

Publisher

Elsevier BV

Subject

Urology

Reference60 articles.

1. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop;Jarow;Urology,2014

2. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group;Kamat;J Clin Oncol,2016

3. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG;Lerner;Bladder cancer (Amsterdam, Netherlands),2015

4. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry;Administration,2018

5. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement;Moher;Int J Surg,2010

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer?;Current Opinion in Urology;2024-08-20

2. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection;European Urology;2024-08

3. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial;Nature Medicine;2024-06-06

4. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial;The Lancet Oncology;2024-06

5. Documento multidisciplinar de consenso sobre el tratamiento actual del tumor vesical no-músculo invasor que no responde al tratamiento con bacilo Calmette-Guérin;Actas Urológicas Españolas;2024-05